cardiologyESC 2026: Five stories that mattered in MunichLast weekend, from August 28 to 31, the European Society of Cardiology (ESC) held its annual congress in Munich. For the biotech industry, ESC 2026 delivered a mixed bag: a cardiac myosin inhibitor opening … more ➔
RNA TechnologiesMolecular surgery: How Europe can lead the worldKJ Muldoon’s survival was not just a medical breakthrough. It was a glimpse of a new category of medicine, in which a genetic error can be corrected with the precision of an operation rather than developed … more ➔
clinical dataBioNTech cancer vaccine trial halted after survival imbalanceBioNTech and Genentech have terminated a Phase 2 trial of their personalized mRNA cancer vaccine autogene cevumeran in colorectal cancer after more deaths occurred in the vaccine arm than among patients … more ➔
licensingHeidelberg Pharma deepens ADC alliance with HuadongGerman biotech Heidelberg Pharma and China-based Huadong Medicine are drawing ever closer: What began as a licensing partnership has developed into an alliance spanning capital investment, joint ADC … more ➔
startupsRevealis enters cancer vaccine race with TEIPP strategyDutch startup Revealis Biotherapeutics has launched to develop a new generation of cancer vaccines targeting tumor cells that have become difficult for T cells to recognize, building on an academic program … more ➔
CollaborationOsivax and GC Biopharma partner on broader flu vaccineFrench biotech Osivax and South Korea-based GC Biopharma have partnered to develop a seasonal influenza vaccine combining Osivax’s broad-spectrum OVX836 candidate with GC Biopharma’s marketed GC … more ➔
Financing RoundRedx raises $36M to fund Phase 2 Crohn’s disease trialUK-based Redx Pharma has closed a $36 million (€31 million) Series A financing round to support a Phase 2 trial of its Crohn’s disease drug candidate. more ➔
Infectious diseaseBerlin-developed Ebola vaccine heads toward African trialThe Coalition for Epidemic Preparedness Innovations (CEPI) is providing Egyptian biopharmaceutical company Minapharm with up to $16.5 million (€14 million) to advance another vaccine candidate against … more ➔
NeurologyHow biotech is treating epilepsy beyond seizuresFor decades, epilepsy treatment has focused on stopping seizures, but for the third of patients whose seizures resist existing medicines, that approach is not enough. As genetics, neural circuits, and … more ➔
clinical dataApollo vaccine triggers broad rhinovirus immunity in Phase 1UK biotech Apollo Therapeutics has reported early Phase 1 data showing that one dose of its experimental rhinovirus vaccine, APL-10456, induced immune responses recognizing all three rhinovirus species … more ➔
